Biotech Values

[exwannabe]

SPPI: isovarin valuation.

Spectrum has the US and Canadian rights to isovarin, which presently has ex-US sales of $200m/year. So what's the US sales expected (asumming no FDA hitch, it already cleared an AC)? It is used with high dose methotrexate or 5-FU, or these as common in the US as elsewhere?

If it generates $200mm for SPPI in 2009, that would certainly justify a somewhat higher market cap, ignoring Satraplat.